Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
| (NASDAQ: OCGN) | Delayed: 0.76 +0.05 (7.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.71 | 52 Week High | $ | |||
| Open | $0.72 | 52 Week Low | $ | |||
| Day High | $0.78 | P/E | N/A | |||
| Day Low | $0.71 | EPS | $ | |||
| Volume | 2,881,446 | |||||
